Pharmaceutical companies are increasingly using patient intelligence to understand treatment experiences, identify unmet needs and support drug development, according to Talking Medicines.
Advances in breast cancer treatment have increased the importance of understanding how patients respond to different therapies, including side effects, treatment choices and quality of life.
Clinical and molecular data provide important evidence, but patient conversations can offer additional insight into how treatments affect everyday lives.
Talking Medicines uses artificial intelligence and data science to analyse patient conversations, helping pharmaceutical companies identify treatment experiences, patient concerns and areas of unmet need.
The company highlights breast cancer as an example of why pharmaceutical research needs to consider patient experiences alongside clinical evidence, particularly as new treatments and personalised approaches change treatment pathways.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
